2,8 dihydroxy-adenine urolithiasis: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
No edit summary
 
(7 intermediate revisions by 2 users not shown)
Line 9: Line 9:
   ICDO          = |
   ICDO          = |
   OMIM          = 102600  |
   OMIM          = 102600  |
  MedlinePlus    = |
  eMedicineSubj  = |
  eMedicineTopic = |
  MeshName      = |
  MeshNumber    = |
}}
}}
{{SI}}
{{SI}}
Line 22: Line 17:


==Overview==
==Overview==
2,8 dihydroxy-adenine urolithiasis is a genetic disorder, in which deficiency of the enzyme [[adenine phosphoribosyltransferase]] leads to [[nephrolithiasis]], permanent kidney damage and eventually [[chronic renal failure]].
2,8 dihydroxy-adenine urolithiasis is a genetic disorder in which deficiency of the enzyme [[adenine phosphoribosyltransferase]] leads to [[nephrolithiasis]], permanent kidney damage and eventually [[chronic renal failure]].


==Pathophysiology==
==Pathophysiology==
===Genetics===
===Genetics===
*It is an [[autosomal recessive disorder]] associated with a [[mutation]] in the enzyme [[adenine phosphoribosyltransferase]].
*The disease is an [[autosomal recessive disorder]] associated with a [[mutation]] in the enzyme [[adenine phosphoribosyltransferase]].
*It catalyzes the formation of [[AMP]] from [[adenine]] and [[phosphoribosylpyrophosphate]]. It can act as a salvage enzyme for recycling of [[adenine]] into [[nucleic acids]].
*The enzyme catalyzes the formation of [[AMP]] from [[adenine]] and [[phosphoribosylpyrophosphate]]. It can act as a salvage enzyme to recycle [[adenine]] into [[nucleic acids]].
*Deficiency of this enzyme leads to excess formation and hyperexcretion of 2,8 dihydroxy adenine (DHA) into [[urine]].
*Deficiency of this enzyme leads to excess formation and hyperexcretion of 2,8 dihydroxy adenine (DHA) into [[urine]].
*Low solubility of DHA results in precipitation of this compound and form crystals and stones.
*Low solubility of DHA results in precipitation of this compound and the formation of crystals and stones.


==Epidemiology and Demographics==
*More than 300 individuals with this disorder have been reported so far, out of which two thirds were from Japan, and a substantial number from France and Iceland.
*The estimated prevalence of APRT deficiency is 0.5 to 1 per 100,000 in the Caucasian population, 0.25 to 0.5 per 100,000 in the Japanese population and in Iceland the estimated point prevalence is 8.9/100,000 <ref name="pmid3193517">{{cite journal |author=Kamatani N, Sonoda T, Nishioka K |title=Distribution of patients with 2,8-dihydroxyadenine urolithiasis and adenine phosphoribosyltransferase deficiency in Japan |journal=[[The Journal of Urology]] |volume=140 |issue=6 |pages=1470–2 |year=1988 |month=December |pmid=3193517 |doi= |url=}}</ref> <ref name="pmid11532677">{{cite journal |author=Edvardsson V, Palsson R, Olafsson I, Hjaltadottir G, Laxdal T |title=Clinical features and genotype of adenine phosphoribosyltransferase deficiency in iceland |journal=[[American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation]] |volume=38 |issue=3 |pages=473–80 |year=2001 |month=September |pmid=11532677 |doi= |url=}}</ref>
==Natural History, Complications and Prognosis==
===Complications===
*[[Nephrolithiasis]]
*[[Chronic renal failure]]
==Diagnosis==
===Symptoms===
*Associated with [[renal stones]]:
**[[Colic]]ky pain
**[[Hematuria]]
**[[Dysuria]]
**[[Oliguria]]
**Reddish brown diaper spots in younger children
*Associated with [[chronic renal failure]]:
**[[Nausea]]/ [[Vomiting]]
**[[Weakness]] and [[fatigue]]
**[[Anorexia]] and [[weight loss]]
*Occasionally, patients may also complain of eye discomfort.
===Physical examination===
====Appearance of the Patient====
*Patient may appear to be in distress from [[colicky flank pain]] and/or [[uremia]]
====Vital Signs====
In advanced cases with signs of [[chronic renal failure]],
*[[Blood pressure]] may be elevated.
*Patient may be [[Tachypnea|tachypneic]] from [[metabolic acidosis]] associated with [[uremia]].
====Eyes====
*[[Conjunctiva]] may appear [[Hyperemia|hyperemic]] from eye discomfort.
====Heart====
*Patients with renal compromise may have a ventricular [[heave]].
*Auscultation
**S4 may be heard
**[[Pericardial friction rub]] in those with chronic [[uremia]].
====Lungs====
*Auscultation
**[[Crackles]]
**Decreased breath sounds from [[pulmonary edema]] in those who develop [[chronic renal failure]].
===Laboratory Findings===
Early recognition and treatment of APRT deficiency is crucial in preventing irreversible damage to the [[kidneys]].
====Urinalysis====
*Stone analysis: 2,8 DHA crystals are readily detectable in the urine.
*[[Crystalluria]]: The small and medium sized crystals have a central maltese cross pattern on polarized light microscopy whereas the large crystals do not as they are impermeable to light .
====Blood tests====
*APRT activity in hemolysates of erythrocytes.
====X ray====
*2,8 Dihydro adenine stones are radiolucent, hence not detected on X-ray films.
====CT====
*[[Renal stones]] are easily detectable on [[CT scan]].
====Ultrasonography====
*[[Ultrasonography]] is highly sensitive for detecting [[renal stones]].
====Spectrophotometry and Crystallography====
*Easily differentiates 2,8 DHA stones from [[uric acid]] stones.
====Genetic Testing====
*Identifying mutations in both copies of the APRT gene.
==Treatment==
===Pharmacotherapy===
*[[Allopurinol]]: 5-10 mg/kg/day (maximum dose of 600-800 mg/day).  Side effects include skin [[rash]] and [[gastrointestinal intolerance]], [[hypersensitivity]].
*Patients who do not tolerate [[allopurinol]], febuxostat (a xanthine oxidase inhibitor) or oxypurinol (a xanthine dehydrogenase inhibitor) should be considered.
===Patient Education===
*Plenty of fluids
*Dietary [[purine]] restriction.
===Follow up===
*Patients treated with [[allopurinol]] can be followed up by monitoring urine microscopy.
===Surgery and Device based therapy===
*Approximately 30% of patients require intervention for stone removal
**Extracorporeal shock-wave lithotripsy,
**Lithotomy and
**Endourological procedures
==References==
{{reflist|2}}


==See also==
==See also==
* [[Adenine phosphoribosyltransferase]]
* [[Adenine phosphoribosyltransferase]]


{{genetic-disorder-stub}}pockychipz
{{genetic-disorder-stub}}
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Genetic disorders]]

Latest revision as of 15:56, 6 August 2012

2,8 dihydroxy-adenine urolithiasis
ICD-10 E79
ICD-9 277.2
OMIM 102600
DiseasesDB 32632

WikiDoc Resources for 2,8 dihydroxy-adenine urolithiasis

Articles

Most recent articles on 2,8 dihydroxy-adenine urolithiasis

Most cited articles on 2,8 dihydroxy-adenine urolithiasis

Review articles on 2,8 dihydroxy-adenine urolithiasis

Articles on 2,8 dihydroxy-adenine urolithiasis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on 2,8 dihydroxy-adenine urolithiasis

Images of 2,8 dihydroxy-adenine urolithiasis

Photos of 2,8 dihydroxy-adenine urolithiasis

Podcasts & MP3s on 2,8 dihydroxy-adenine urolithiasis

Videos on 2,8 dihydroxy-adenine urolithiasis

Evidence Based Medicine

Cochrane Collaboration on 2,8 dihydroxy-adenine urolithiasis

Bandolier on 2,8 dihydroxy-adenine urolithiasis

TRIP on 2,8 dihydroxy-adenine urolithiasis

Clinical Trials

Ongoing Trials on 2,8 dihydroxy-adenine urolithiasis at Clinical Trials.gov

Trial results on 2,8 dihydroxy-adenine urolithiasis

Clinical Trials on 2,8 dihydroxy-adenine urolithiasis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on 2,8 dihydroxy-adenine urolithiasis

NICE Guidance on 2,8 dihydroxy-adenine urolithiasis

NHS PRODIGY Guidance

FDA on 2,8 dihydroxy-adenine urolithiasis

CDC on 2,8 dihydroxy-adenine urolithiasis

Books

Books on 2,8 dihydroxy-adenine urolithiasis

News

2,8 dihydroxy-adenine urolithiasis in the news

Be alerted to news on 2,8 dihydroxy-adenine urolithiasis

News trends on 2,8 dihydroxy-adenine urolithiasis

Commentary

Blogs on 2,8 dihydroxy-adenine urolithiasis

Definitions

Definitions of 2,8 dihydroxy-adenine urolithiasis

Patient Resources / Community

Patient resources on 2,8 dihydroxy-adenine urolithiasis

Discussion groups on 2,8 dihydroxy-adenine urolithiasis

Patient Handouts on 2,8 dihydroxy-adenine urolithiasis

Directions to Hospitals Treating 2,8 dihydroxy-adenine urolithiasis

Risk calculators and risk factors for 2,8 dihydroxy-adenine urolithiasis

Healthcare Provider Resources

Symptoms of 2,8 dihydroxy-adenine urolithiasis

Causes & Risk Factors for 2,8 dihydroxy-adenine urolithiasis

Diagnostic studies for 2,8 dihydroxy-adenine urolithiasis

Treatment of 2,8 dihydroxy-adenine urolithiasis

Continuing Medical Education (CME)

CME Programs on 2,8 dihydroxy-adenine urolithiasis

International

2,8 dihydroxy-adenine urolithiasis en Espanol

2,8 dihydroxy-adenine urolithiasis en Francais

Business

2,8 dihydroxy-adenine urolithiasis in the Marketplace

Patents on 2,8 dihydroxy-adenine urolithiasis

Experimental / Informatics

List of terms related to 2,8 dihydroxy-adenine urolithiasis

File:Autorecessive.svg Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]

Synonyms and keywords: Adenine phosphoribosyltransferase deficiency; AMP pyrophorylase deficiency; APRT deficiency

Overview

2,8 dihydroxy-adenine urolithiasis is a genetic disorder in which deficiency of the enzyme adenine phosphoribosyltransferase leads to nephrolithiasis, permanent kidney damage and eventually chronic renal failure.

Pathophysiology

Genetics

Epidemiology and Demographics

  • More than 300 individuals with this disorder have been reported so far, out of which two thirds were from Japan, and a substantial number from France and Iceland.
  • The estimated prevalence of APRT deficiency is 0.5 to 1 per 100,000 in the Caucasian population, 0.25 to 0.5 per 100,000 in the Japanese population and in Iceland the estimated point prevalence is 8.9/100,000 [1] [2]

Natural History, Complications and Prognosis

Complications

Diagnosis

Symptoms

Physical examination

Appearance of the Patient

Vital Signs

In advanced cases with signs of chronic renal failure,

Eyes

Heart

Lungs

Laboratory Findings

Early recognition and treatment of APRT deficiency is crucial in preventing irreversible damage to the kidneys.

Urinalysis

  • Stone analysis: 2,8 DHA crystals are readily detectable in the urine.
  • Crystalluria: The small and medium sized crystals have a central maltese cross pattern on polarized light microscopy whereas the large crystals do not as they are impermeable to light .

Blood tests

  • APRT activity in hemolysates of erythrocytes.

X ray

  • 2,8 Dihydro adenine stones are radiolucent, hence not detected on X-ray films.

CT

Ultrasonography

Spectrophotometry and Crystallography

  • Easily differentiates 2,8 DHA stones from uric acid stones.

Genetic Testing

  • Identifying mutations in both copies of the APRT gene.

Treatment

Pharmacotherapy

Patient Education

  • Plenty of fluids
  • Dietary purine restriction.

Follow up

  • Patients treated with allopurinol can be followed up by monitoring urine microscopy.

Surgery and Device based therapy

  • Approximately 30% of patients require intervention for stone removal
    • Extracorporeal shock-wave lithotripsy,
    • Lithotomy and
    • Endourological procedures

References

  1. Kamatani N, Sonoda T, Nishioka K (1988). "Distribution of patients with 2,8-dihydroxyadenine urolithiasis and adenine phosphoribosyltransferase deficiency in Japan". The Journal of Urology. 140 (6): 1470–2. PMID 3193517. Unknown parameter |month= ignored (help)
  2. Edvardsson V, Palsson R, Olafsson I, Hjaltadottir G, Laxdal T (2001). "Clinical features and genotype of adenine phosphoribosyltransferase deficiency in iceland". American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 38 (3): 473–80. PMID 11532677. Unknown parameter |month= ignored (help)

See also

Template:Genetic-disorder-stub

Template:WikiDoc Sources